BioCentury
ARTICLE | Company News

Gilead, AbbVie, Bristol-Myers sales and marketing update

August 3, 2015 7:00 AM UTC

The U.K.’s NICE published three draft guidances recommending Daklinza daclatasvir from Bristol-Myers, Viekirax ombitasvir/paritaprevir and Exviera dasabuvir from AbbVie and Harvoni ledipasvir/sofosbuvir from Gilead for certain populations of HCV patients.

NICE recommended a 12-week course of Daklinza plus Gilead’s Sovaldi sofosbuvir for non-cirrhotic HCV genotype 1 and 4 patients with significant fibrosis who have been previously treated or who are ineligible or intolerant of interferon. The draft guidance did not recommend Daklinza plus Sovaldi for untreated genotype 1 or 4 patients nor for those with genotype 3 infection. The average list price of a 12-week course of Daklinza plus Sovaldi is L59,501 ($92,280). ...